MLTX
MLTX
KY61559X1045
MoonLake Immunotherapeutics
Loading chart...

Financials

Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
Breakdown 2025 2024 Change %
Total Revenue -- --
--
Cost of Revenue -- --
--
Gross Profit -- --
--
244.834.000 143.091.000
71.1%
Operating Income -244.834.000 -143.091.000
71.1%
Pretax Income -229.710.000 -120.962.000
89.9%
Net Income Common Stockholders -227.318.000 -118.936.000
91.1%
-- --
--
-- --
--
ende